보고서 요약(국문)

시장 개요
A형 간염 백신은 A형 간염을 예방하는 백신입니다. A형 간염은 A형 간염 바이러스에 의해 발생하는 간 질환으로, 경증에서 중증에 이르기까지 다양한 증상을 나타냅니다. A형 간염 바이러스(HAV)는 오염된 음식이나 물을 섭취하거나 감염자와 직접 접촉함으로써 전염됩니다. 이 질병은 주기적으로 재발하여 전 세계적으로 유행병을 일으키는 경향이 있습니다. 질병에 대한 반응으로 생성된 항체는 평생 지속되며 재감염을 예방하는데, 가장 효과적인 방법은 백신 접종입니다. 백신은 6개월 간격으로 두 번 접종합니다.
A형 간염 백신 시장 성장을 견인하는 주요 요인은 전 세계적으로 A형 간염 발병률이 증가함에 따라 백신 접종의 중요성이 커지고 있다는 점입니다. A형 간염 환자 수 증가는 각국 정부와 의료 기관이 질병에 대한 인식을 높이고 위험 지역에서 백신 접종을 강화하도록 유도합니다. 또한 시장 참여자들의 지속적인 A형 간염 백신 보급 노력도 시장 성장을 촉진하고 있습니다.

A형 간염 백신 시장 동향 및 분석
정부의 예방 노력 강화
A형 간염 백신은 급증하는 A형 간염 발병률을 낮추는 데 사용됩니다. 미국 질병통제예방센터(CDC)에 따르면, 2018년 미국에서는 총 12,474건의 A형 간염 사례가 보고되었으며, 진단되지 않은 사례를 포함하면 실제 발병 건수는 24,900건에 달할 것으로 추정됩니다. 이러한 상황은 각국 정부가 A형 간염에 대한 인식 제고, 진단, 치료 및 예방 접종 노력을 강화하도록 촉진했습니다. 2022년 4월 21일 기준, WHO 유럽 지역 11개국과 WHO 미주 지역 1개국에서 원인 불명의 급성 간염 사례가 최소 169건 보고되었습니다. WHO에 따르면, 위생 환경과 위생 습관이 미흡한 선진국에서는 10세 이전에 약 90%의 어린이가 A형 간염 바이러스에 감염됩니다. 개발도상국의 정부 예방접종 프로그램은 전 세계 A형 간염 백신 시장 성장을 견인하고 있습니다.
반면, A형 간염 질환에 대한 개인의 인식 부족은 예측 기간 동안 세계 시장 성장을 저해할 주요 요인으로 작용할 것으로 예상됩니다. 또한, 진단에 대한 거부감 역시 시장 성장을 저해하는 요소입니다.
A형 간염 백신 시장 세분화 분석
불활성화 백신 부문은 예측 기간 동안 시장을 주도할 것으로 예상됩니다.
불활성화 백신은 2019년 세계 시장을 지배했으며, 향후에도 상당한 성장을 보일 것으로 전망됩니다. 불활성화 백신은 안전하고 효과가 뛰어납니다. 전통적으로는 2회 접종이 권장되며, 특히 A형 간염 감염 위험이 높은 여행객이나 면역억제 환자에게 권장됩니다. 그러나 건강한 사람의 경우 1회 접종으로도 동등한 효능을 얻을 수 있다는 연구 결과가 발표되었습니다. 이러한 점이 향후 불활성화 백신 부문의 성장을 촉진할 것으로 예상됩니다.
적용 분야별로는 정부 기관이 예측 기간 동안 세계 시장에서 지배적인 위치를 차지할 것으로 전망됩니다. 환자들은 A형 간염 진단 및 적절한 예방 접종을 위해 공공 의료 시설에 의존하고 있으며, 이는 예측 기간 동안 해당 부문의 성장을 뒷받침합니다. 또한, 예방 접종 캠페인을 제공하는 정부 프로그램의 증가로 인해 예측 기간 동안 상당한 연평균 성장률(CAGR)이 예상됩니다.
글로벌 A형 간염 백신 시장 지역별 점유율
아시아 태평양 지역이 글로벌 A형 간염 백신 시장을 주도할 것으로 예상됩니다.
아시아 태평양 지역은 2021년 글로벌 A형 간염 백신 시장에서 지배적인 위치를 차지했습니다. 아시아 태평양 지역 내에서 중국은 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 중국에서는 생백신 형태의 A형 간염 백신이 질병 퇴치에 유리한 요소로 자리 잡고 있습니다. 또한, 유럽은 예측 기간 동안 가치 측면에서 상당한 성장을 보일 것으로 예상됩니다. 비교적 저렴한 가격으로 백신을 쉽게 구할 수 있다는 점이 이 지역 시장 성장을 촉진할 것으로 예상됩니다. 아시아 태평양 지역의 A형 간염 백신 시장은 정부 정책 및 프로그램, 특히 인도와 중국의 지원에 힘입어 예측 기간 동안 빠른 성장을 보일 것으로 예상됩니다. 또한 소아 인구 증가와 예방 접종에 대한 인식 제고로 인해 인도와 중국과 같은 신흥 경제국에서 A형 간염 백신 수요가 증가하고 있으며, 이는 아시아 태평양 지역의 A형 간염 백신 시장 성장을 더욱 촉진할 것으로 전망됩니다.
A형 간염 백신 시장 기업 및 경쟁 환경:
A형 간염 백신 시장은 주요 시장 참여 기업들로 인해 경쟁이 매우 치열합니다. 세계 시장 성장에 기여하는 주요 A형 간염 백신 기업으로는 GlaxoSmithKline, Merck & Co. Inc., Sanofi, Sinovac, Zhejiang Pukang, Changchun Institute of Biological, KM Biologics, IMBCA, ChangSheng, Convac 등이 있습니다. 주요 기업들은 A형 간염 백신 시장에서의 글로벌 성장을 위해 새로운 확장 전략을 채택하고 있습니다.

COVID-19가 A형 간염 백신 시장에 미치는 영향
세계 A형 간염 백신 시장에 대한 부정적 영향
COVID-19 발생은 전 세계 A형 간염 백신 시장의 성장에 부정적인 영향을 미쳤습니다. 팬데믹 상황 속에서 공급망 차질이 시장 성장에 큰 타격을 입혔습니다. COVID-19 백신 개발, 제품 유형 및 유통에 대한 관심이 집중되면서 A형 간염 백신에 대한 수요는 감소했습니다. 따라서 COVID-19 팬데믹은 2021년 A형 간염 백신 시장 가치를 저해했습니다.
본 글로벌 A형 간염 백신 시장 보고서는 약 48개의 시장 데이터 표, 43개의 그림 및 190페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Market Overview
Hepatitis A vaccine is a vaccine that prevents hepatitis A. The disease is a liver disorder caused by the hepatitis A virus leading from mild to severe illness. The Hepatitis A Virus (HAV) is transferred through either ingestion of contaminated food and water or direct contact with an infectious person. The disease has a propensity for cyclic reappearances, which occurs in epidemics globally. The antibodies introduced in response to the disease last through life and protect against the recurrence of infection, the best way for which is through vaccination. It is given in two doses injected six months apart.
The major factors propelling the growth of the Hepatitis A vaccine market are the increasing prevalence of hepatitis A globally, which leads to increasing concerns for vaccination. The rise in the number of Hepatitis A cases propels the national governments and healthcare organizations to introduce steps to increase awareness about the disease and manage vaccination drives in risk-prone areas. Further continuous efforts by the market players to promote Hepatitis A vaccines drive the market growth.
Hepatitis A Vaccine Market Trends and Dynamics
Increasing government initiatives for prevention
Hepatitis A Vaccine is used to submerge the rising cases of Hepatitis A. As per the Center for Disease Control, in 2018, the U.S. reported a total of 12,474 hepatitis A cases, and the organization estimated the actual number of cases reported in the year to be 24,900 owing to the undiagnosed cases. This has propelled governments to increase their efforts for awareness, diagnosis, treatment, and vaccination. As of 21 April 2022, at least 169 cases of acute hepatitis of unknown origin have been reported from 11 countries in the WHO European Region and one country in the WHO Region of the Americas. According to the WHO, approximately 90.0% of children are infected with the hepatitis A virus before 10 years in developed countries with inadequate sanitary conditions and sanitation habits. Government vaccination programs are propelling the worldwide market for hepatitis A vaccines in developing countries.
On the other hand, lack of awareness concerning the Hepatitis A disease among individuals is a key factor expected to curtail the global market's growth over the forecast period. Moreover, resistance among the population for diagnosis also obstructs market growth.
Hepatitis A Vaccine Market Segmentation Analysis
Inactivated vaccine segment is projected to be the dominant segment in the market during the forecast period
Inactivated vaccines dominated the global market in 2019, also it is expected to present considerable growth shortly. Inactivated Vaccines are safe and highly functional. A two-dose schedule is traditionally recommended, particularly for travelers at significant risk of contracting hepatitis A and immunocompromised individuals. However, with a single dosage, equivalent efficacy has been achieved in stable people. This is expected to propel segmental growth soon.
Based on application, government institutions held the dominant position in the global market during the forecast period. Patients depend on public healthcare facilities for diagnosis and proper vaccination of Hepatitis A, supporting the segment growth during the forecast period. Moreover, the surging government programs offering vaccination drives are expected to project a considerable CAGR during the forecast period.
Global Hepatitis A Vaccine Market Geographical Share
Asia-Pacific is expected to dominate the global Hepatitis A Vaccine market
Asia-Pacific held a dominant position in the global Hepatitis A Vaccine market in 2021. In Asia-Pacific, China is expected to represent considerable growth during the forecast period. As in China, the live attenuated Hepatitis A Vaccine is becoming a favorable element to tackle the disease. Moreover, Europe is expected to represent significant growth in terms of value during the forecast period. The easy availability of vaccines at a comparatively lower cost is expected to propel market growth across the region. The Hepatitis A Vaccine market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by government policies and programs, especially in India and China. Moreover, the rise in the pediatric population and increased awareness about vaccination results in increasing demand for Hepatitis A Vaccine in emerging economies, such as India and China, which is expected to augment Asia Pacific's growth Hepatitis A Vaccine market.
Hepatitis A Vaccine Market Companies and Competitive Landscape:
The Hepatitis A Vaccine market is highly competitive, owing to the presence of major market players. The key Hepatitis A Vaccine player contributing to the global market's growth include GlaxoSmithKline, Merck & Co. Inc., Sanofi, Sinovac, Zhejiang Pukang, Changchun Institute of Biological, KM Biologics, IMBCA, ChangSheng, Convac, among others. The major players are adopting new expansion strategies for global growth in the Hepatitis A Vaccine market.
COVID-19 Impact on Hepatitis A Vaccine Market
Negative impact on the global Hepatitis A Vaccine market
The outbreak of COVID-19 has negatively impacted the growth of the Hepatitis A Vaccine market globally. The disruption in the supply chain has majorly impacted the growth of the market amidst the pandemic. The escalated focus on COVID-19 vaccine development, product type, and distribution has led to de-escalation in Hepatitis A vaccines. Therefore, the COVID-19 pandemic has hampered the market value of the Hepatitis A Vaccine market in 2021
The global Hepatitis A Vaccine market report would provide an access to approximately 48 market data tables, 43 figures and 190 pages.

상세 목차

1. Scope and Methodology
1.1. Research Methodology
1.2. Scope of the Market
2. Key Trends and Developments
3. Executive Summary
3.1. Market Snippet by Product Type
3.2. Market Snippet by Application
3.3. Market Snippet by Region
4. Market Dynamics
4.1. Market impacting factors
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Impact analysis
5. Industry Analysis
5.1. Porter's five forces analysis
5.2. Supply Chain analysis
5.3. PEST Analysis
5.4. Pricing Analysis
5.5. Reimbursement Analysis
5.6. Regulatory Analysis
5.7. Unmet Needs
5.8. Patent Trends
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
7. By Product Type
7.1. Introduction
7.1.1. Market size analysis, and y-o-y growth analysis (%), By Product Type Segment
7.1.2. Market attractiveness index, By Product Type Segment
7.2. Inactivated Vaccine*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
7.3. Live Attenuated Vaccine
8. By Application
8.1. Introduction
8.1.1. Market size analysis, and y-o-y growth analysis (%), By Application Segment
8.1.2. Market attractiveness index, By Application Segment
8.2. Government Institution *
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
8.3. Private Sector
8.4. Other
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key region-specific dynamics
9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. South America
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
9.3.5.1. Brazil
9.3.5.2. Argentina
9.3.5.3. Rest of South America
9.4. Europe
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
9.4.5.1. Germany
9.4.5.2. U.K.
9.4.5.3. France
9.4.5.4. Spain
9.4.5.5. Italy
9.4.5.6. Rest of Europe
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
10. Competitive Landscape
10.1. Competitive scenario
10.2. Competitor strategy analysis
10.3. Market positioning/share analysis
10.4. Mergers and acquisitions analysis
11. Company Profiles
11.1. GlaxoSmithKline *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Merck & Co., Inc.
11.3. Sanofi
11.4. Sinovac
11.5. Zhejiang Pukang
11.6. Changchun Institute of Biological
11.7. KM Biologics
11.8. IMBCA
11.9. ChangSheng
11.10. Convac(*List not Exhaustive*)
12. DataM Intelligence
12.1. Appendix
12.2. About us and services
12.3. Contact us

언급된 주요 기업들

GlaxoSmithKline, Merck & Co., Inc., Sanofi, Sinovac, Zhejiang Pukang, Changchun Institute of Biological, KM Biologics, IMBCA, ChangSheng

표 목록 (Tables)

List of Tables

Table 1 Global Hepatitis A Vaccine Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Hepatitis A Vaccine Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Hepatitis A Vaccine Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 4 North America Hepatitis A Vaccine Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 5 North America Hepatitis A Vaccine Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 6 North America Hepatitis A Vaccine Market Value, By Country, 2022-2031 (US$ Million)

Table 7 South America Hepatitis A Vaccine Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 8 South America Hepatitis A Vaccine Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 9 South America Hepatitis A Vaccine Market Value, By Country, 2022-2031 (US$ Million)

Table 10 Europe Hepatitis A Vaccine Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 11 Europe Hepatitis A Vaccine Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 12 Europe Hepatitis A Vaccine Market Value, By Country, 2022-2031 (US$ Million)

Table 13 Asia Pacific Hepatitis A Vaccine Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 14 Asia Pacific Hepatitis A Vaccine Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 15 Asia Pacific Hepatitis A Vaccine Market Value, By Country, 2023, 2027 & 2031 (US$ Million)

Table 16 The Middle East & Africa Hepatitis A Vaccine Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 17 The Middle East & Africa Hepatitis A Vaccine Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 18 The Middle East & Africa Hepatitis A Vaccine Market Value, By Country, 2023, 2027 & 2031 (US$ Million)

Table 19 GlaxoSmithKline: Overview

Table 20 GlaxoSmithKline: Product Type Portfolio

Table 21 GlaxoSmithKline: Key Developments

Table 22 Merck & Co., Inc.: Overview

Table 23 Merck & Co., Inc. : Product Type Portfolio

Table 24 Merck & Co., Inc.: Key Developments

Table 25 Sanofi: Overview

Table 26 Sanofi: Product Type Portfolio

Table 27 Sanofi: Key Developments

Table 28 Sinovac: Overview

Table 29 Sinovac: Product Type Portfolio

Table 30 Sinovac: Key Developments

Table 31 Zhejiang Pukang: Overview

Table 32 Zhejiang Pukang: Product Type Portfolio

Table 33 Zhejiang Pukang: Key Developments

Table 34 Changchun Institute of Biological: Overview

Table 35 Changchun Institute of Biological: Product Type Portfolio

Table 36 Changchun Institute of Biological: Key Developments

Table 37 KM BIOLOGICS: Overview

Table 38 KM BIOLOGICS: Product Type Portfolio

Table 39 KM BIOLOGICS: Key Developments

Table 40 IMBCA: Overview

Table 41 IMBCA: Product Type Portfolio

Table 42 IMBCA: Key Developments

Table 43 CHANGSHENG: Overview

Table 44 CHANGSHENG: Product Type Portfolio

Table 45 CHANGSHENG: Key Developments

Table 46 Convac: Overview

Table 47 Convac: Product Type Portfolio

Table 48 Convac: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Hepatitis A Vaccine Market Share, By Product Type, 2022 & 2031 (%)

Figure 2 Global Hepatitis A Vaccine Market Share, By Application, 2022 & 2031 (%)

Figure 3 Global Hepatitis A Vaccine Market Share, By Region, 2022 & 2031 (%)

Figure 4 Global Hepatitis A Vaccine Market Value, 2022-2031 (US$ Million)

Figure 5 Global Hepatitis A Vaccine Market Y-o-Y Growth, By Product Type, 2022-2031 (%)

Figure 6 Inactivated Vaccine: Global Hepatitis A Vaccine Market Value, 2022-2031 (US$ Million)

Figure 7 Live Attenuated Vaccine: Global Hepatitis A Vaccine Market Value, 2022-2031 (US$ Million)

Figure 8 Global Hepatitis A Vaccine Market Y-o-Y Growth, By Application, 2022-2031 (%)

Figure 9 Government Institution: Global Hepatitis A Vaccine Market Value, 2022-2031 (US$ Million)

Figure 10 Private Sector: Global Hepatitis A Vaccine Market Value, 2022-2031 (US$ Million)

Figure 11 Other: Global Hepatitis A Vaccine Market Value, 2022-2031 (US$ Million)

Figure 12 Global Hepatitis A Vaccine Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 13 North America Hepatitis A Vaccine Market Value, 2022-2031 (US$ Million)

Figure 14 North America Hepatitis A Vaccine Market Share, By Product Type, 2022 & 2031 (%)

Figure 15 North America Hepatitis A Vaccine Market Share, By Application, 2022 & 2031 (%)

Figure 16 North America Hepatitis A Vaccine Market Share, By Product Type, 2022 & 2031 (%)

Figure 17 North America Hepatitis A Vaccine Market Share, By Country, 2022 & 2031 (%)

Figure 18 South America Hepatitis A Vaccine Market Value, 2022-2031 (US$ Million)

Figure 19 South America Hepatitis A Vaccine Market Share, By Product Type, 2022 & 2031 (%)

Figure 20 South America Hepatitis A Vaccine Market Share, By Application, 2022 & 2031 (%)

Figure 21 South America Hepatitis A Vaccine Market Share, By Country, 2022 & 2031 (%)

Figure 22 Europe Hepatitis A Vaccine Market Value, 2022-2031 (US$ Million)

Figure 23 Europe Hepatitis A Vaccine Market Share, By Product Type, 2022 & 2031 (%)

Figure 24 Europe Hepatitis A Vaccine Market Share, By Application, 2022 & 2031 (%)

Figure 25 Europe Hepatitis A Vaccine Market Share, By Country, 2022 & 2031 (%)

Figure 26 Asia-Pacific Hepatitis A Vaccine Market Value, 2022-2031 (US$ Million)

Figure 27 Asia-Pacific Hepatitis A Vaccine Market Share, By Product Type, 2022 & 2031 (%)

Figure 28 Asia-Pacific Hepatitis A Vaccine Market Share, By Application, 2022 & 2031 (%)

Figure 29 Asia-Pacific Hepatitis A Vaccine Market Share, By Country, 2022 & 2031 (%)

Figure 30 The Middle East & Africa Hepatitis A Vaccine Market Value, 2022-2031 (US$ Million)

Figure 31 The Middle East & Africa Hepatitis A Vaccine Market Share, By Product Type, 2022 & 2031 (%)

Figure 32 The Middle East & Africa Hepatitis A Vaccine Market Share, By Application, 2022 & 2031 (%)

Figure 33 The Middle East & Africa Hepatitis A Vaccine Market Share, By Country, 2022 & 2031 (%)

Figure 34 GlaxoSmithKline: Financials

Figure 35 MERCK & Co., Inc.: Financials

Figure 36 SANOFI: Financials

Figure 37 Sinovac: Financials

Figure 38 Zhejiang Pukang: Financials

Figure 39 Changchun Institute of Biological: Financials

Figure 40 KM BIOLOGICS: Financials

Figure 41 IMBCA: Financials

Figure 42 CHANGSHENG: Financials

Figure 43 Convac: Financials